Kintara Therapeutics Inc (KTRA)

[Rkmatters]

They are going for base hits and will turn those into a run. Once they statistically prove in the phase III trial that the drug extends OS in patients who have failed all other salvage therapy in refractory GBM, then they will be able to get label extensions in other indications. Brilliant entry into refractory, get some FDA wins on the books.

And then they will start the process of going straight for the standard of care market. For instance, the testing in newly diagnosed GBM is starting soon. Patients who don't respond to temodar will be enrolled to start VAL-083. They'll eventually do the same with lung and ovarian cancers. But the intentions is to sell the drug to big Pharma, and they'll take the drug development the rest of the way. We'll end up with a big payout. :)